Measuring cardiac power output -- the acid test.

tor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–96. [4] The EPISTENT Investigators. Randomised placebocontrolled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoproteinIIb/IIIa blockade. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352: 87–92. [5] Zwart-van Rijkom JEF, van Hout BA. Cost-efficacy in interventional cardiology: results from the EPISTENT study. Eur Heart J 2001; 22: 1476–84. [6] Weintraub WS, Thompson TD, Culler S et al. Targeting patients undergoing angioplasty for thrombus inhibition: a cost-effectiveness and decision support model. Circulation 2000; 102: 392–8. [7] Mark DB, Talley JD, Topol EJ et al. Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. Circulation 1996; 94: 629–35. [8] Weintraub WS, Culler S, Boccuzzi SJ et al. Economic impact of GPIIB/IIIA blockade after high-risk angioplasty: results from the RESTORE trial. Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis. J Am Coll Cardiol 1999; 34: 1061–6. [9] Lincoff AM, Mark DB, Tcheng JE et al. Economic assessment of platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization: Results from the EPILOG Circulation. 2000; 102: 2923–9. [10] Cohen DJ, Krumholz HM, Sukin CA et al. for the Stent Restenosis Study Investigators. In-hospital and one-year economic outcomes after coronary stenting or balloon angioplasty: results from a randomized clinical trial. Circulation 1995; 92: 2480–7. [11] Loomes G, McKenzie L. The use of QALYs in health care decision making. Soc Sci Med 1989; 28: 299–308. [12] Cook TA, O’Regan M, Galland RB. Quality of life following percutaneous transluminal angioplasty for claudication. Euro J Vasc Endovasc Surg 1996; 11: 191–4. [13] Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1990: 128–9. [14] Drummond MF, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes. Oxford, England: Oxford University Press; 1990: 127–8. [15] Borna S, Sundaram S. An approach to allocating limited health resources. J Health Soc Behav 1999; 11: 85–94. [16] Gold MR, Siegel JE, Russell LB, Weinstein MC. Costeffectiveness in health and medicine. New York: Oxford University Press, 1996.